Search results for "acids"

showing 10 items of 3520 documents

Homozygous Familial Hypercholesterolemia in Spain Prevalence and Phenotype-Genotype Relationship

2016

Background— Homozygous familial hypercholesterolemia (HoFH) is a rare disease characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) and extremely high risk of premature atherosclerotic cardiovascular disease. HoFH is caused by mutations in several genes, including LDL receptor ( LDLR ), apolipoprotein B ( APOB ), proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), and LDL protein receptor adaptor 1 ( LDLRAP1 ). No epidemiological studies have assessed HoFH prevalence or the clinical and molecular characteristics of this condition. Here, we aimed to characterize HoFH in Spain. Methods and Results— Data were collected from the Spanish Dyslipidemia Regist…

Male0301 basic medicineOncologyLdl receptor geneApolipoprotein BLipid-lowering therapyFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosity0302 clinical medicineAutosomal-dominant hypercholesterolemiaRisk FactorsEpidemiologyPrevalenceDiseaseRegistriesGenetics (clinical)Molecular EpidemiologybiologyhypercholesterolemiaHomozygoteDouble-blindMiddle AgedPhenotypeCardiovascular DiseasesApolipoprotein B-100allelesFemalelipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineMutationsAdultGenetic MarkersHeterozygotemedicine.medical_specialtyInhibitorAdolescentPlacebo-controlled trialHyperlipoproteinemia Type IIlipidsYoung Adult03 medical and health sciencesInternal medicineGeneticsmedicineHumansGenetic Predisposition to DiseaseAlleleAdaptor Proteins Signal TransducingRecessive hypercholesterolemiaPCSK9registriesCholesterol LDLApolipoprotein-bmedicine.disease030104 developmental biologyEndocrinologyReceptors LDLSpainMutationLDL receptorbiology.proteinmutationDyslipidemia
researchProduct

Daptomycin for children in clinical practice experience

2016

Data on daptomycin use in the pediatric setting are scanty. We conducted a multicenter, retrospective study on 46 children treated with intravenous daptomycin at a mean dosage of 7.0 mg/kg/d, for a median of 14 days. Three children had adverse events possibly related to daptomycin. The drug was overall well tolerated, even with prolonged treatment.

Male0301 basic medicinePediatricsmedicine.disease_causePediatrics0302 clinical medicinepolycyclic compounds030212 general & internal medicineChildChildrenMedicine (all)OsteomyelitisBacterial InfectionsPerinatology and Child HealthAnti-Bacterial AgentsClinical PracticeInfectious DiseasesChild PreschoolAdministration IntravenousFemalelipids (amino acids peptides and proteins)Children; Daptomycin; Methicillin-resistant Staphylococcus aureus; Osteomyelitis; Sepsis; Pediatrics Perinatology and Child Health; Medicine (all); Microbiology (medical); Infectious DiseasesMethicillin-resistant Staphylococcus aureusmedicine.drugMicrobiology (medical)medicine.medical_specialtyAdolescentDrug-Related Side Effects and Adverse Reactions030106 microbiologyChildren; Daptomycin; Methicillin-resistant Staphylococcus aureus; Osteomyelitis; Sepsis;Sepsis03 medical and health sciencesDaptomycinSepsismedicineHumansAdverse effectRetrospective Studiesbusiness.industryOsteomyelitisInfant NewbornInfantRetrospective cohort studybiochemical phenomena metabolism and nutritionbacterial infections and mycosesmedicine.diseaseMethicillin-resistant Staphylococcus aureuscarbohydrates (lipids)Pediatrics Perinatology and Child HealthDaptomycinbusinessProlonged treatment
researchProduct

Comparative Study of the Effects Exerted by N-Valproyl-L-Phenylalanine and N-valproyl-L-tryptophan on CA1 Hippocampal Epileptiform Activity in Rat

2018

Background: The research on the improvement of epilepsy therapy is constantly growing. Valproyl-LPhenylalanine (VPA-Phen) and N-valproyl-L-tryptophan (VPA-Tryp) were synthesized to increase the antiepileptic efficacy of valproic acid. Methods: VPA-Phen and VPA-Tryp were comparatively tested on CA1 hippocampal epileptiform bursting activity obtained by increasing potassium and lowering calcium and magnesium concentrations in the fluid perfusing rat brain slices. Each slice was treated with a single concentration (0.2, 0.5, 1 mM) of VPA-Phen or VPA-Tryp. Both burst duration and interburst frequency, during and after treatment, were off-line compared with baseline values. For both parameters,…

Male0301 basic medicinePhenylalaninePotassiumchemistry.chemical_elementPharmacologyHippocampal formationCalciumInhibitory postsynaptic potentialHippocampusSettore BIO/09 - Fisiologia03 medical and health sciencesantiepileptic drug0302 clinical medicineDrug DiscoveryN-valproyl-L-tryptophanvalproic acid.medicineAnimalshippocampal epilepsyRats WistarPharmacologyValproic AcidEpilepsyValproyl-L-Phenylalanine (VPA-Phen)Dipeptidesinterictal burstRat brainAmino-acidic derivativeRats030104 developmental biologychemistryAnticonvulsantslipids (amino acids peptides and proteins)030217 neurology & neurosurgerymedicine.drugN-valproyl-L-phenylalanineCurrent Pharmaceutical Design
researchProduct

Stable Oxidative Cytosine Modifications Accumulate in Cardiac Mesenchymal Cells From Type2 Diabetes Patients

2018

Rationale: Human cardiac mesenchymal cells (CMSCs) are a therapeutically relevant primary cell population. Diabetes mellitus compromises CMSC function as consequence of metabolic alterations and incorporation of stable epigenetic changes. Objective: To investigate the role of α-ketoglutarate (αKG) in the epimetabolic control of DNA demethylation in CMSCs. Methods and Results: Quantitative global analysis, methylated and hydroxymethylated DNA sequencing, and gene-specific GC methylation detection revealed an accumulation of 5-methylcytosine, 5-hydroxymethylcytosine, and 5-formylcytosine in the genomic DNA of human CMSCs isolated from diabetic donors. Whole heart genomic DNA analysis reveale…

Male0301 basic medicinePhysiologyPopulationheartBiologyMixed Function OxygenasesCytosineMice03 medical and health sciencesProto-Oncogene ProteinsfibroblastsHuman Umbilical Vein Endothelial CellsAnimalsHumansMyocytes CardiacEpigeneticsEnzyme InhibitorseducationCells CulturedEpigenomicsDemethylationeducation.field_of_studyDNA methylationDNA methylation; epigenomics; fibroblasts; heart; hyperglycemia; metabolism; physiology; cardiology and cardiovascular medicineMesenchymal Stem CellsSettore MED/13 - ENDOCRINOLOGIABase excision repairMolecular biologyThymine DNA GlycosylaseMice Inbred C57BLHEK293 Cells030104 developmental biologyDNA demethylationDiabetes Mellitus Type 2epigenomicsDNA methylationKetoglutaric AcidshyperglycemiaThymine-DNA glycosylaseCardiology and Cardiovascular MedicineOxidation-ReductionmetabolismCirculation Research
researchProduct

Polyphenol intake and cardiovascular risk factors in a population with type 2 diabetes: The TOSCA.IT study

2017

Background: The role of polyphenol intake on cardiovascular risk factors is little explored, particularly in people with diabetes. Aim: To evaluate the association between the intake of total polyphenols and polyphenol classes with the major cardiovascular risk factors in a population with type 2 diabetes. Methods: Dietary habits were investigated in 2573 males and females participants of the TOSCA.IT study. The European Prospective Investigation on Cancer and Nutrition (EPIC) questionnaire was used to assess dietary habits. In all participants, among others, we assessed anthropometry, plasma lipids, blood pressure, C-reactive protein and HbA1c following a standard protocol. The USDA and Ph…

Male0301 basic medicinePhysiologyType 2 diabetes030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineSettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineDietary polyphenolsFlavonoidsPhenolic acidsCardiovascular riskType 2 diabetesLOW-GRADE INFLAMMATIONBLOOD-PRESSUREDIETARY POLYPHENOLSDARK CHOCOLATEINSULIN SENSITIVITYRANDOMIZED-TRIALSDISEASEMETAANALYSISMETABOLISMCHOLESTEROLRisk FactorsSurveys and QuestionnairesHydroxybenzoatesProspective StudiesFood scienceCardiovascular risk; Dietary polyphenols; Flavonoids; Phenolic acids; Type 2 diabeteseducation.field_of_studyPhenolic acidNutrition and Dieteticsbiologyfood and beveragesType 2 diabetesDietary polyphenolMiddle AgedDietary polyphenols; Flavonoids; Phenolic acids; Cardiovascular risk; Type 2 diabetesEuropean Prospective Investigation into Cancer and NutritionDietary polyphenolsCardiovascular DiseasesFemalePhenolic acidsPopulationCardiovascular risk Dietary polyphenols Flavonoids Phenolic acids Type 2 diabetes03 medical and health sciencesDiabetes mellitusmedicineHumanseducationTriglyceridesAgedFlavonoids030109 nutrition & dieteticsDose-Response Relationship Drugbusiness.industryCholesterol HDLC-reactive proteinPolyphenolsCholesterol LDLAnthropometrymedicine.diseaseCardiovascular riskCardiovascular risk; Dietary polyphenols; Flavonoids; Phenolic acids; Type 2 diabetes; Nutrition and Dietetics; Critical Care and Intensive Care MedicineDietCross-Sectional StudiesNutrition AssessmentDiabetes Mellitus Type 2chemistryFlavonoidbiology.proteinGlycated hemoglobinbusinessBody mass index
researchProduct

The desert gerbil Psammomys obesus as a model for metformin-sensitive nutritional type 2 diabetes to protect hepatocellular metabolic damage: Impact …

2017

Introduction While metformin (MET) is the most widely prescribed antidiabetic drug worldwide, its beneficial effects in Psammomys obesus (P. obesus), a rodent model that mimics most of the metabolic features of human diabetes, have not been explored thoroughly. Here, we sought to investigate whether MET might improve insulin sensitivity, glucose homeostasis, lipid profile as well as cellular redox and energy balance in P. obesus maintained on a high energy diet (HED). Materials and methods P. obesus gerbils were randomly assigned to receive either a natural diet (ND) consisting of halophytic plants (control group) or a HED (diabetic group) for a period of 24 weeks. MET (50 mg/kg per os) was…

Male0301 basic medicinePhysiologymedicine.medical_treatment[SDV]Life Sciences [q-bio]Body-WeightRespiratory chainlcsh:MedicineMitochondria LiverBiochemistrychemistry.chemical_compoundLiver Parenchymal-CellsEndocrinologyGlucose MetabolismAnimal CellsKetogenesisMedicine and Health SciencesElectrochemistryGlucose homeostasisGut Microbiotalcsh:ScienceEnergy-Producing OrganellesComputingMilieux_MISCELLANEOUS2. Zero hungerMultidisciplinaryOrganic CompoundsMonosaccharidesFatty AcidsChemical ReactionsLipidsMetforminMitochondria3. Good healthChemistryPhysiological ParametersLiverPhysical SciencesCarbohydrate MetabolismCellular Structures and OrganellesCellular TypesAnatomyOxidation-ReductionResearch Articlemedicine.medical_specialtyIsolated Rat HepatocytesEndocrine DisordersCarbohydratesBioenergeticsBiologyCarbohydrate metabolism03 medical and health sciencesInsulin resistanceInternal medicineFood-IntakeDiabetes MellitusmedicineAnimalsHypoglycemic AgentsObesityRespiratory-Chain[ SDV ] Life Sciences [q-bio]Fatty acid metabolismInsulinBody WeightOrganic Chemistrylcsh:RChemical CompoundsGluconeogenesisBiology and Life SciencesCell Biologymedicine.diseaseGlucose-6-Phosphate HydrolysisDisease Models AnimalGlucoseMetabolism030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2GluconeogenesischemistryMetabolic DisordersHepatocyteslcsh:QInsulin ResistanceGerbillinaeGlucose-ProductionFatty-Acid-MetabolismOxidation-Reduction Reactions
researchProduct

Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation

2020

Background and Aims: Nonalcoholic fatty liver disease (NAFLD) affects a quarter of the adult population. A significant subset of patients are lean, but their underlying pathophysiology is not well understood. Approach and Results: We investigated the role of bile acids (BAs) and the gut microbiome in the pathogenesis of lean NAFLD. BA and fibroblast growth factor (FGF) 19 levels (a surrogate for intestinal farnesoid X receptor [FXR] activity), patatin-like phospholipase domain containing 3 (PNPLA3), and transmembrane 6 superfamily member 2 (TM6SF2) variants, and gut microbiota profiles in lean and nonlean NAFLD were investigated in a cohort of Caucasian patients with biopsy-proven NAFLD (n …

Male0301 basic medicineReceptors Cytoplasmic and NuclearGut floraMice0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisNonalcoholic fatty liver diseasebiologyMiddle AgedNAFLD; bile acids; fibrosis; gut microbiota; leanPhospholipases A2 Calcium-IndependentFemale030211 gastroenterology & hepatologyfibrosiAdultmedicine.medical_specialtydigestive systemBile Acids and SaltsCyclic N-Oxides03 medical and health sciencesThinnessInternal medicineNAFLDmedicinebile acidAnimalsHumansbile acidsHepatologygut microbiotabusiness.industryFGF15fibrosisnutritional and metabolic diseasesFGF19leanmedicine.diseasebiology.organism_classificationNAFLD fibrosis lean bile acids gut microbiotadigestive system diseasesGastrointestinal MicrobiomeFibroblast Growth FactorsMice Inbred C57BLDisease Models Animal030104 developmental biologyEndocrinologyFarnesoid X receptorSteatohepatitisbusinessTropanesTM6SF2
researchProduct

Normalization with Corresponding Naïve Tissue Minimizes Bias Caused by Commercial Reverse Transcription Kits on Quantitative Real-Time PCR Results

2016

Real-time reverse transcription polymerase chain reaction (PCR) is the gold standard for expression analysis. Designed to improve reproducibility and sensitivity, commercial kits are commonly used for the critical step of cDNA synthesis. The present study was designed to determine the impact of these kits. mRNA from mouse brains were pooled to create serial dilutions ranging from 0.0625 μg to 2 μg, which were transcribed into cDNA using four different commercial reverse-transcription kits. Next, we transcribed mRNA from brain tissue after acute brain injury and naïve mice into cDNA for qPCR. Depending on tested genes, some kits failed to show linear results in dilution series and revealed s…

Male0301 basic medicineSerial dilutionlcsh:MedicineGene ExpressioncDNA synthesisArtificial Gene Amplification and ExtensionBioinformaticsBiochemistryPolymerase Chain ReactionMice0302 clinical medicineBrain Injuries Traumaticlcsh:ScienceGenes EssentialMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionMessenger RNAComplementary DNAHousekeeping geneNucleic acidsReverse transcription polymerase chain reactionResearch ArticleNormalization (statistics)DNA ComplementaryForms of DNANucleic acid synthesisBiologyReal-Time Polymerase Chain ReactionResearch and Analysis Methods03 medical and health sciencesExtraction techniquesComplementary DNAGeneticsAnimalsRNA MessengerChemical synthesisRNA synthesisMolecular Biology TechniquesMolecular BiologyGeneMessenger RNABiology and life scienceslcsh:RDNAReverse TranscriptionMolecular biologyRNA extractionReverse transcriptaseMice Inbred C57BLBiosynthetic techniques030104 developmental biologyRNAlcsh:Q030217 neurology & neurosurgeryPLOS ONE
researchProduct

Myristic acid is associated to low plasma HDL cholesterol levels in a Mediterranean population and increases HDL catabolism by enhancing HDL particle…

2016

Background: HDL-C plasma levels are modulated by dietary fatty acid (FA), but studies investigating dietary supplementation in FA gave contrasting results. Saturated FA increased HDL-C levels only in some studies. Mono-unsaturated FA exerted a slight effect while poly-unsaturated FA mostly increased plasma HDL-C. Aims: This study presents two aims: i) to investigate the relationship between HDL-C levels and plasma FA composition in a Sicilian population following a "Mediterranean diet", ii) to investigate if FA that resulted correlated with plasma HDL-C levels in the population study and/or very abundant in the plasma were able to affect HDL catabolism in an "in vitro" model of cultured hep…

Male0301 basic medicineSettore MED/09 - Medicina InternaMediterranean dietCellHepG2 cellMyristic acid030204 cardiovascular system & hematologyDiet MediterraneanMyristic AcidSettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineSicilyeducation.field_of_studyLiver NeoplasmsHep G2 CellsMiddle Agedmedicine.anatomical_structurePopulation studyFemalelipids (amino acids peptides and proteins)Composition (visual arts)Cholesterol EstersCardiology and Cardiovascular MedicinePopulation studyProtein BindingAdultmedicine.medical_specialtyCarcinoma HepatocellularPopulationHDL cholesterol level03 medical and health sciencesInternal medicinemedicineHumanseducationAgedFatty acids; HDL cholesterol levels; HepG2 cells; Population study; Cardiology and Cardiovascular MedicineCatabolismbusiness.industryCholesterolCholesterol HDLMembrane Proteinsnutritional and metabolic diseasesFatty acidKinetics030104 developmental biologyEndocrinologychemistrybusinessBiomarkersHeparan Sulfate ProteoglycansAtherosclerosis
researchProduct

Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report

2016

Objective— Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors lower low-density lipoprotein (LDL) cholesterol in the vast majority of patients with autosomal dominant familial hypercholesterolemia. Will PCSK9 inhibition with monoclonal antibodies, in particular alirocumab, be of therapeutic value for patients with autosomal recessive hypercholesterolemia (ARH)? Approach and Results— Primary lymphocytes were obtained from 28 genetically characterized ARH patients and 11 controls. ARH lymphocytes treated with mevastatin were incubated with increasing doses of recombinant PCSK9 with or without saturating concentrations of alirocumab. Cell surface LDL receptor expression measured…

Male0301 basic medicineSettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]receptorsalirocumabFamilial hypercholesterolemia030204 cardiovascular system & hematologyproprotein convertase subtilisin kexin type 90302 clinical medicinetherapeuticsLymphocytesCells CulturedhypercholesterolemiaAnticholesteremic AgentsPCSK9 InhibitorsAntibodies MonoclonalMiddle Aged3. Good healthPhenotypeAutosomal Recessive HypercholesterolemiaKexinDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)LovastatinProprotein Convertase 9Cardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtySerine Proteinase InhibitorsAdolescentBiologyAntibodies Monoclonal HumanizedLDLYoung Adult03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseLovastatinAdaptor Proteins Signal TransducingAlirocumabPCSK9receptors LDLCholesterol LDLmedicine.diseaseProprotein convertasetherapeutic030104 developmental biologyEndocrinologyCase-Control Studiesalirocumab; hypercholesterolemia; proprotein convertase subtilisin kexin type 9; receptors LDL; therapeutics; Cardiology and Cardiovascular MedicineMutationLDL receptorHydroxymethylglutaryl-CoA Reductase InhibitorsArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct